Compare PD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | XERS |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | 435 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.5M | 965.6M |
| IPO Year | 2019 | 2021 |
| Metric | PD | XERS |
|---|---|---|
| Price | $7.58 | $5.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $17.00 | $10.43 |
| AVG Volume (30 Days) | ★ 3.5M | 2.0M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.71 | ★ 100.00 |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $467,499,000.00 | $49,590,000.00 |
| Revenue This Year | $8.16 | $28.65 |
| Revenue Next Year | $3.75 | $18.33 |
| P/E Ratio | $4.60 | ★ N/A |
| Revenue Growth | 8.54 | ★ 142.67 |
| 52 Week Low | $6.18 | $3.81 |
| 52 Week High | $19.70 | $10.08 |
| Indicator | PD | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 30.81 |
| Support Level | $6.18 | $4.30 |
| Resistance Level | $16.48 | $7.21 |
| Average True Range (ATR) | 0.37 | 0.38 |
| MACD | 0.29 | -0.07 |
| Stochastic Oscillator | 74.40 | 15.56 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.